The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells

Antioxidants and Redox Signaling

Volumn 7, Issue 5-6, 2005, Pages 630-638

  Dukes, April A ^a   Korwek, Kimberly M ^a   Hastings, Teresa G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ADENOSINE TRIPHOSPHATE; CATECHOL; DOPA; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METIROSINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ALPHA-METHYLTYROSINE; ANIMALS; CATECHOLS; CELL SURVIVAL; DOPAMINE; ENZYME INHIBITORS; METHAMPHETAMINE; OXIDATION-REDUCTION; PC12 CELLS; RATS; ROTENONE; TYROSINE 3-MONOOXYGENASE;

EID: 17644384487     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.630     Document Type: Article

References (57)

1. Basma AN, Morris EJ, Nicklas WJ, and Geller HM. L-Dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem 64: 825-832, 1995.
2. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131, 2003.
3. Ben-Yoseph O, Boxer PA, and Ross BD. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress. J Neurochem 66: 2329-2337, 1996.
4. Berman SB and Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73: 1127-1137, 1999.
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 301-306, 2000.
6. Blandini F, Nappi G, and Greenamyre JT. Quantitative study of mitochondrial complex 1 in platelets of Parkinsonian patients. Mov Disord 13: 11-15, 1998.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
8. Brown JM and Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99: 45-53, 2003.
9. Cubells JF, Rayport S, Rajendran G, and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14: 2260-2271, 1994.
10. Dauer W and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39: 889-909, 2003.
11. Dawson TM and Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822, 2003.
12. Di Monte DA. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2: 531-538, 2003.
13. Filloux F and Townsend JJ. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119: 79-88, 1993.
14. Fornstedt B, Bergh I, Rosengren E, and Carlsson A. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J Neurochem 54: 578-586, 1990.
15. Fumagalli F, Gainetdinov RR, Valenzano KJ, and Caron MG. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18: 4861-4869, 1998.
16. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643, 1978.
17. Greenamyre JT, Betarbet R, and Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9 Suppl 2: S59-S64, 2003.
18. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623, 1992.
19. Hartley A, Stone JM, Heron C, Cooper JM, and Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63: 1987-1990, 1994.
20. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthesis. J Neurochem 59: 1609-1623, 1995.
21. 3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 63: 1126-1132, 1994.
22. Hastings TG, Lewis DA, and Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93: 1956-1961, 1996.
23. Hoglinger GU, Feger J, Prigent A, Michel PP, Parain K, Champy P, Ruberg M, Oertel WH, and Hirsch EC. Chronic systemic complex 1 inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem 84: 491-502, 2003.
24. Jakel RJ and Maragos WF. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 23: 239-245, 2000.
25. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3: S26-S36, 2003.
26. +)-related compounds in rat pheochromocytoma PC12 cells. Arch Biochem Biophys 337: 75-80, 1997.
27. Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, and Kopin IJ. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 868: 191-201, 2000.
28. Lavoie MJ and Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19: 1484-1491, 1999.
29. Li H and Dryhurst G. Irreversible inhibition of mitochondrial complex 1 by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem 69: 1530-1541, 1997.
30. Lotharius J and O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 275: 38581-38588, 2000.
31. Lotharius J and O'Malley KL. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann Neurol 49: 79-89, 2001.
32. Maker HS, Weiss C, Silides DJ, and Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36: 589-593, 1981.
33. Mattammal MB, Haring JH, Chung HD, Raghu G, and Strong R. An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4: 271-281, 1995.
34. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, and Di Monte DA. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10: 119-127, 2002.
35. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, and Kagawa Y. Deficiencies in complex 1 subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163: 1450-1455, 1989.
36. O'Lague PH, Huttner SL, Vandenberg CA, Morrison-Graham K, and Horn R. Morphological properties and membrane channels of the growth cones induced in PC12 cells by nerve growth factor. J Neurosci Res 13: 301-321, 1985.
37. Pifl C, Giros B, and Caron MG. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13: 4246-4253, 1993.
38. Pitkanen S and Robinson BH. Mitochondrial complex 1 deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 98: 345-351, 1996.
39. Rabinovic AD, Lewis DA, and Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101: 67-76, 2000.
40. Ronner P, Friel E, Czerniawski K, and Frankle S. Luminometric assays of ATP, phosphocreatine, and creatine for estimation of free ADP and free AMP. Anal Biochem 275: 208-216, 1999.
41. Sakka N, Sawada H, Izumi Y, Kume T, Katsuki H, Kaneko S, Shimohama S, and Akaike A. Dopamine is involved in selectivity of dopaminergic neuronal death by rotenone. Neuroreport 14: 2425-2428, 2003.
42. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, and Marsden CD. Mitochondrial complex 1 deficiency in Parkinson's disease. Lancet 1: 1269, 1989.
43. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, and Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54: 823-827, 1990.
44. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, and Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145, 1990.
45. Seyfried J, Soldner F, Kunz WS, Schulz JB, Klockgether T, Kovar KA, and Wullner U. Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochem Int 36: 489-497, 2000.
46. Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, and Osawa T. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74: 589-597, 2003.
47. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, and Greenamyre JT. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22: 7006-7015, 2002.
48. Sherer TB, Kim JH, Betarbet R, and Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179: 9-16, 2003.
49. Sherer TB, Betarbet R, Kim JH, and Greenamyre JT. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341: 87-90, 2003.
50. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kirn JH, Miller GW, Yagi T, Matsuno-Yagi A, and Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23: 10756-10764, 2003.
51. Shimizu K, Matsubara K, Ohtaki K, Fujimaru S, Saito O, and Shiono H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res 976: 243-252, 2003.
52. Shoffner JM, Watts RL, Juncos JL, Torroni A, and Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30: 332-339, 1991.
53. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71: 2112-2122, 1998.
54. Taylor SC, Shaw SM, and Peers C. Mitochondrial inhibitors evoke catecholamine release from pheochromocytoma cells. Biochem Biophys Res Commun 273: 17-21, 2000.
55. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100: 5473-5478, 2003.
56. Tse DC, McCreery RL, and Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 19: 37-40, 1976.
57. m-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79: 266-277, 2001.